These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 15447998)
1. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998 [TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310 [TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968 [TBL] [Abstract][Full Text] [Related]
4. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575 [TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication. Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707 [TBL] [Abstract][Full Text] [Related]
6. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230 [TBL] [Abstract][Full Text] [Related]
7. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer]. Yu ZH; Wang YC; Chen LB; Song Y; Liu C; Xia XY; Lin Q; Ma CY Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):284-7. PubMed ID: 18788633 [TBL] [Abstract][Full Text] [Related]
8. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069 [TBL] [Abstract][Full Text] [Related]
9. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Li J; El-Naggar A; Mao L Cancer; 2005 Aug; 104(4):771-6. PubMed ID: 15959912 [TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. De Schutter H; Geeraerts H; Verbeken E; Nuyts S Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529 [TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006 [TBL] [Abstract][Full Text] [Related]
13. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Marsit CJ; Karagas MR; Danaee H; Liu M; Andrew A; Schned A; Nelson HH; Kelsey KT Carcinogenesis; 2006 Jan; 27(1):112-6. PubMed ID: 15987713 [TBL] [Abstract][Full Text] [Related]
14. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703 [TBL] [Abstract][Full Text] [Related]
15. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700 [TBL] [Abstract][Full Text] [Related]
16. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Harden SV; Tokumaru Y; Westra WH; Goodman S; Ahrendt SA; Yang SC; Sidransky D Clin Cancer Res; 2003 Apr; 9(4):1370-5. PubMed ID: 12684406 [TBL] [Abstract][Full Text] [Related]
17. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865 [TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855 [TBL] [Abstract][Full Text] [Related]
19. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Kim YT; Lee SH; Sung SW; Kim JH Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047 [TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]